TH165802A - Method for activating helper T cells - Google Patents
Method for activating helper T cellsInfo
- Publication number
- TH165802A TH165802A TH1501003333A TH1501003333A TH165802A TH 165802 A TH165802 A TH 165802A TH 1501003333 A TH1501003333 A TH 1501003333A TH 1501003333 A TH1501003333 A TH 1501003333A TH 165802 A TH165802 A TH 165802A
- Authority
- TH
- Thailand
- Prior art keywords
- hla
- molecule
- drb1
- peptide
- helper
- Prior art date
Links
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 title claims abstract 7
- 230000003213 activating Effects 0.000 title claims abstract 5
- 102100020485 HLA-DRB1 Human genes 0.000 claims abstract 20
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims abstract 20
- 102100005617 HLA-DQB1 Human genes 0.000 claims abstract 7
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims abstract 7
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract 5
- 210000004027 cells Anatomy 0.000 claims abstract 5
- 239000000427 antigen Substances 0.000 claims abstract 4
- 102000038129 antigens Human genes 0.000 claims abstract 4
- 108091007172 antigens Proteins 0.000 claims abstract 4
- 230000020411 cell activation Effects 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- 230000014509 gene expression Effects 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 210000002443 helper T lymphocyte Anatomy 0.000 claims 1
- 101710035186 BoLA-DQB Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
Abstract
แก้ไข 14/08/2558 1501003333 การประดิษฐ์นี้เกี่ยวข้องกับวิธีสำหรับการแอคติเวต เฮลเปอร์ T เซลล์ ซึ่งรวมถึง ขั้นตอน แอคทิเวติง เฮลเปอร์ T เซลล์ ด้วยการเติม WT1 เปปไทด์ ลงในแอนติเจนพรีเซนติงเซลล์ ที่ซึ่ง WT1 เปปไทด์มีความสามารถยึดจับกับ MHC คลาส II โมเลกุลที่เลือกจาก HLA-DRB1*0802 โมเลกุล, HLA-DRB1*13:02 โมเลกุล, HLA-DRB1*14:03 โมเลกุล, HLA-DRB1*14:05 โมเลกุล, HLA- DQB1*03:02 โมเลกุล และ HLA-DQB1*04:01 โมเลกุล ------------------------------------------------ จบรวม 1 หน้า ---------------------------------------------------------------------------- คำขอใหม่ปรับปรุงวันที่ 20/04/2559 การประดิษฐนี้เกี่ยวข้องกับวิธีสำหรับการแอคติเวต เฮลเปอร์ T เซลล์ ซึ่งรวมถึงขั้นตอนของ การแอคติเวต เฮลเปอร์ T เซลล์ ด้วยการเติม WT1 เปปไทด์ลงในแอนติเจนพรีเซนติงเซลล์ ที่ซึ่ง WT1 เปปไทด์มีความสามารถยึดจับกับ MHC คลาส II โมเลกุลที่เลือกจาก HLA-DRB1*08:02 โมเลกุล, HLA-DRB1*13:02 โมเลกุล, HLA-DRB1*14:03 โมเลกุล, HLA-DRB1*14:05 โมเลกุล, HLA- DQB1*03:02 โมเลกุล และ HLA-DQB1*04:01 โมเลกุล: สิทธิบัตรยา EDIT 14/08/2015 1501003333 This invention involves a method for activating helper T cells, including the T cell activation helper step by adding WT1 peptide to the antigen. Presenting cells where the WT1 peptide has the ability to bind to MHC class II molecules selected from HLA-DRB1 * 0802 molecule, HLA-DRB1 * 13: 02 molecule, HLA-DRB1 * 14: 03 molecule, HLA-DRB1 * 14: 05 molecule, HLA- DQB1 * 03: 02 molecule and HLA-DQB1 * 04: 01 molecule. Molecules ------------------------------------------------ End Total 1 page ----------------------------------------------- ----------------------------- New request updated 20/04/2016 This invention relates to a method for activating. T cell helper, which includes the activation phase of T cell helper, by adding WT1 peptide to the presentering antigen where WT1 peptide is able to bind. With MHC class II molecules selected from HLA-DRB1 * 08: 02 molecule, HLA-DRB1 * 13: 02 molecule, HLA-DRB1 * 14: 03 molecule, HLA-DRB1 * 14: 05 molecule, HLA- DQB1 * 03: 02 molecule and HLA-DQB1 * 04 molecule. : 01 molecules: drug patent
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH165802A true TH165802A (en) | 2017-08-10 |
| TH165802B TH165802B (en) | 2017-08-10 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123932T1 (en) | STRUCTURES OF POLYSPECIFIC ANTIBODY | |
| PH12015501361B1 (en) | Method for activating helper t cell | |
| CL2020000919A1 (en) | Specific antibodies cd47 / pd-l1. | |
| MX2020001198A (en) | Binding agents binding to pd-l1 and cd137 and use thereof. | |
| BR112019010972A2 (en) | t-cell receptors and immunotherapy using the same | |
| MX2018008436A (en) | Method for activating helper t cell. | |
| EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
| CY1121335T1 (en) | ANTI-CXCR3 ANTIBODIES | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| BR112016025352A2 (en) | methods of producing a library of eukaryotic cell clones, method of producing a diverse repertoire of ligands, screening method for a cell of a desired phenotype, screening method for a target-recognizing ligand, library, in vitro library of eukaryotic cell clones, eukaryotic cell-containing container, use of a site-specific nuclease, library uses, method for converting single chain antibody (scfv) populations to immunoglobulin (ig) or fragment, and method for reformatting of any two dna elements attached to a vector | |
| BR112016030462A2 (en) | binding molecules, one or more isolated polynucleotides, one or more vectors, host cell, method of producing a binding molecule, pharmaceutical composition, use of the binding molecule, method of treating disease and inducing target cell lysis | |
| EA201790953A1 (en) | CHANGES IN THE EXPRESSION OF GENE IN CART-CELLS AND THEIR APPLICATION | |
| UY35456A (en) | UNION MOLECULES FOR BCMA AND CD3 | |
| BR112018006547A2 (en) | pd-1 antibodies and uses thereof | |
| BR112017005110A2 (en) | isolated monoclonal antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, pharmaceutical composition, and method for lowering blood glucose levels or for treating a condition or disease. | |
| BR112012024710A8 (en) | molecules that bind to the antigen, their production processes, as well as the pharmaceutical composition that comprise them | |
| BR112016014284A2 (en) | isolated caninized antibody or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, pharmaceutical composition, and methods for enhancing the activity of an immune cell and for producing a caninized antibody or antigen binding fragment the same | |
| PE20230321A1 (en) | NEW PEPTIDES AND NEW PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| BR112015014751A2 (en) | human anti-tau antibodies | |
| BR112016016916A8 (en) | use of an antibody that binds to active plasma kallikrein for treatment of hereditary angiodema (hae) | |
| UA115657C2 (en) | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| BR112017006598A2 (en) | human derived antidipeptide repeat antibody (dprs) | |
| PE20180481A1 (en) | UNION TO TAU ANTIBODIES | |
| NZ730450A (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| BR112016030983A8 (en) | compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes, kit, method for preparing tyrphostin 9 and use |